Table 1. Baseline input values used for cost-saving analyses.

Parameter	Baseline value	Reference
Direct medical cost for screening ($)
Quantitative method	17.76
Semi-quantitative method	0.86
Direct nonmedical cost ($)
Transportation	9.265
Indirect medical costs for healthcare ($)
End-stage renal disease	13,149.62	HIRA annual report
Cardiovascular disease	25,634.48	HIRA annual report
All-cause mortality	6,810.38	HIRA annual report
Incidences of clinical outcomes, normo-albuminuria (per year)
End-stage renal disease	0.0154	Ref 14
Cardiovascular disease	0.0095	Ref 14
All-cause mortality	0.0006	Ref 13
Relative hazards of clinical outcomes, albuminuria versus normo-albuminuria*
End-stage renal disease	3.432 (95% CI, 2.757–4.271)	Fig 2
Cardiovascular disease	1.315 (95% CI, 1.250–1.384)	Fig 2
All-cause mortality	1.480 (95% CI, 1.408–1.556)	Fig 2
Probabilities (distribution)
Negative at quantitative screening	Beta (917, 193)**	Table 2
Negative at semi-quantitative screening	Beta (615, 495)**	Table 2
False negative among the negative population at SemiQ screening	Beta (36, 579)**	Table 2
True positive at Q test confirmation among the positive population at SemiQ test screening	Beta (157, 338)**	Table 2

* These values were used to estimate incidences of clinical outcomes among participants with albuminuria.

** Beta distribution.